Zurampic Protects Pancreatic β-Cells from High Uric Acid Induced-Damage by Inhibiting URAT1 and Inactivating the ROS/AMPK/ERK Pathways | Zendy

Ying Xin | Zendy; Kun Wang | Zendy; Zhaotong Jia | Zendy; Tao Xu | Zendy; Qiang Xu | Zendy; Chao Zhang | Zendy; Jia Liu | Zendy; Rui Chen | Zendy; Zhongcai Du | Zendy; Jianjing Sun | Zendy

Open Access

Zurampic Protects Pancreatic β-Cells from High Uric Acid Induced-Damage by Inhibiting URAT1 and Inactivating the ROS/AMPK/ERK Pathways

Author(s) -

Ying Xin,

Kun Wang,

Zhaotong Jia,

Tao Xu,

Qiang Xu,

Chao Zhang,

Jia Liu,

Rui Chen,

Zhongcai Du,

Jianjing Sun

Publication year - 2018

Publication title -

cellular physiology and biochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.486

H-Index - 87

eISSN - 1421-9778

pISSN - 1015-8987

DOI - 10.1159/000490184

Subject(s) - uric acid , ampk , viability assay , mapk/erk pathway , chemistry , apoptosis , phosphorylation , microbiology and biotechnology , medicine , biochemistry , protein kinase a , biology

Zurampic is a US FDA approved drug for treatment of gout. However, the influence of Zurampic on pancreatic β-cells remains unclear. The study aimed to evaluate the effects of Zurampic on high uric acid-induced damage of pancreatic β-cells and the possible underlying mechanisms.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research